Art Clapp is a highly experienced pharmaceutical executive with over 30 years of experience successfully developing, launching and commercializing OTC and Rx drugs. He has launched some of the largest blockbusters in dermatology including Cetaphil which is now a $1B brand, Differin the largest acne brand and others. With his scientific background and understanding of skin diseases he is highly skillful at formulating highly effective and innovative topical OTC products. He holds scientific degrees in Biology, Biochemistry and an MBA. His skills in marketing and commercializing products helped Galderma grow from a multi-million-dollar company to a multi-billion-dollar company in 20 years. After retiring from Galderma, one of the largest global dermatology pharmaceutical companies as VP of Business development, he founded Nuvothera, an OTC consumer healthcare company that develops and sells highly effective OTC products for treating skin diseases. He was joined by some of his colleagues at Galderma including Mike Yankovoy, CFO and Bev Hope, Director of Marketing and they have successfully launched several products. They are now scaling their business after securing distribution at the largest retail drugstore chains including CVS and Walgreens and are in discussions with Rite Aid for distribution in the spring.
